119-HR-8205 Journalist Public Summary
119 · HR 8205 Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
A bipartisan House bill would extend and fine‑tune a 2021 ALS law through fiscal year 2031, keep federal research and access programs running, tighten oversight of trial‑grant renewals, and require the FDA to publish an updated five‑year plan for ALS and other rare neurodegenerative diseases; it advanced out of committee 46–0 on May 21, 2026.
Public Summary
Headline Summary: Extends and updates a 2021 ALS law through 2031 to keep research and treatment‑access efforts going, add checks on clinical‑trial grants, and require an updated FDA plan for rare neurodegenerative diseases.
What It Does: The bill reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It strengthens the grant program by having HHS review patient‑enrollment progress when a project seeks renewal and by asking drug makers to share interim clinical‑trial data. It clarifies that “phase 3” trials include combined phase 2/3 and planned phase 3 studies not yet enrolling. It directs the FDA to post, within one year of enactment, a report with a refreshed five‑year action plan and a look‑back on the 2022 plan’s impact across ALS and other rare neurodegenerative diseases. It also asks GAO for a follow‑up evaluation four years after enactment and notes Congress’s support for directly appropriating funds to run the program.
Why It Matters: For people living with ALS and related conditions, steady funding and clearer FDA planning aim to speed up promising therapies, improve transparency around trials, and coordinate efforts beyond ALS to other rare neurodegenerative diseases.
- Who’s For It: Bipartisan sponsors—Reps. Mike Quigley (D‑IL) and Ken Calvert (R‑CA)—and the House Energy & Commerce Committee, which advanced it 46–0 on May 21, 2026.
- Who’s For It: Patients, caregivers, and advocacy groups are likely to back continued funding and an updated FDA roadmap aimed at faster, more coordinated therapy development.
- Who’s Against It: No recorded opposition in committee (0 nays). Potential concerns could include cost (the bill signals support for direct appropriations) and industry worries about sharing interim clinical‑trial data.
What’s Next: As of May 21, 2026, the bill was ordered reported by the House Energy & Commerce Committee. The next step is a House floor vote; if it passes, it moves to the Senate and, if approved there, to the President.
Discussion